Kura Oncology Receives $135 Million Milestone Payment as KOMZIFTI Achieves First Commercial Sale
核心洞察
Kura Oncology completed the first U.S. commercial sale of KOMZIFTI (搜索) (ziftomenib), triggering a $135 million milestone payment from partner Kyowa Kirin expected before year-end.
KOMZIFTI (搜索) is an FDA-approved once-daily oral menin (搜索) inhibitor for treating adults with relapsed or refractory NPM1 (搜索)-mutated acute myeloid leukemia, approved on November 13, 2025.
The milestone payment represents a significant commercial achievement under Kura's collaboration and license agreement with Kyowa Kirin for the precision oncology treatment.
Kura Oncology announced the completion of the first U.S. commercial sale of KOMZIFTI (搜索) (ziftomenib), marking a significant milestone for the biopharmaceutical company's precision oncology program. The achievement triggers a $135 million payment from collaboration partner Kyowa Kirin, which Kura expects to receive prior to year-end.
Commercial Launch Achievement
KOMZIFTI (搜索) received FDA approval on November 13, 2025, and has now successfully transitioned to commercial availability. The drug represents Kura's first commercialized product, developed as a once-daily, oral menin (搜索) inhibitor specifically designed for treating adults with relapsed or refractory NPM1 (搜索)-mutated acute myeloid leukemia.
Under the collaboration and license agreement between Kura Oncology and Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc., the first commercial sale milestone activates the substantial payment structure established in their partnership. This $135 million payment demonstrates the commercial potential recognized by Kyowa Kirin in KOMZIFTI (搜索)'s therapeutic profile.
Precision Medicine Approach
KOMZIFTI (搜索) targets a specific genetic mutation in acute myeloid leukemia patients, representing Kura's commitment to precision medicine approaches in cancer treatment. The drug functions as a menin (搜索) inhibitor, addressing cancer signaling pathways in patients with NPM1 (搜索)-mutated disease, a subset of acute myeloid leukemia cases with distinct molecular characteristics.
Kura Oncology has positioned itself as a biopharmaceutical company focused on realizing precision medicines for cancer treatment. The company's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors.
Strategic Partnership Impact
The milestone payment reflects the value of Kura's collaboration with Kyowa Kirin, established to advance KOMZIFTI (搜索) through development and commercialization. This partnership structure allows Kura to benefit from significant milestone payments while leveraging Kyowa Kirin's commercial capabilities.
Beyond KOMZIFTI (搜索), Kura continues to pioneer advancements in menin (搜索) inhibition and farnesyl transferase inhibition, suggesting a broader pipeline of precision oncology candidates targeting similar molecular pathways in cancer treatment.